Want to see IBRX full AI Analyst Report?
IBRX Stock Chart & Stats
$7.70
-$0.11(-4.03%)
At close: 4:00 PM EST
$7.70
-$0.11(-4.03%)
Day’s Range― - ―
52-Week Range$1.95 - $12.43
Previous CloseN/A
Volume1.20M
Average Volume (3M)11.59M
Market Cap
$7.87B
Enterprise Value$8.62K
Total Cash (Recent Filing)$380.88M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding1,047,354,000
10 Day Avg. Volume9,050,971
30 Day Avg. Volume11,585,240
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside68.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$222.35M
Bulls Say, Bears Say
Bulls Say
Commercial Product And Revenue StreamHaving an FDA-approved product (ANKTIVA) establishes a recurring commercial revenue stream and a go-to-market infrastructure. This durable revenue base supports ongoing operations and commercialization investment, reducing sole dependence on R&D milestones over the next several quarters.
Revenue Ramp With Strong Gross MarginScaling to roughly $141M TTM with ~94% gross margin indicates attractive product economics and meaningful commercial traction. If operating costs are managed, these durable unit economics can support a path to improved profitability and reinvestment into sales, supply, and R&D over months.
Exclusive Tokyo-172 BCG U.S. RightsSecuring exclusive 10-year U.S. rights to Tokyo-172 BCG materially strengthens supply diversification and long-term commercial positioning. It reduces dependence on a single BCG source, helps address chronic U.S. shortages, and supports planned regulatory filings and scale-up of bladder cancer offerings.
Bears Say
Large Net Losses And Persistent Cash BurnVery large trailing losses and consistent negative operating and free cash flow imply ongoing external funding needs. Persistent cash burn erodes runway, increases dilution or financing risk, and constrains the company’s ability to sustainably fund commercialization and late-stage development without repeated capital raises.
Negative Shareholders' EquityAccumulated negative equity signals deep historical losses and a weak capital cushion. Even with lower headline debt, negative equity limits financial flexibility, raises investor sensitivity to dilution or restructurings, and reduces the company’s ability to absorb setbacks or fund growth internally.
Regulatory/compliance Risk (FDA Warning Letter)An FDA warning letter tied to ANKTIVA promotion creates enduring regulatory and compliance risk. Corrective actions can limit promotional activities, increase compliance costs, and heighten scrutiny on commercialization practices, potentially slowing uptake and complicating long-term market development.
ImmunityBio News
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $1.95 and its highest was $12.43 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $7.87B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on May 07, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.55.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.09.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 1,047,354,000 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -7.399%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (68.83% Upside)
$13.00 (68.83% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 133.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
112.88%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
IBRX Stock 12 Month Forecast
Average Price Target
$13.00
▲(68.83% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
62.90% Insiders
4.10% Mutual Funds
0.22% Other Institutional Investors
25.45% Public Companies and Individual Investors